Skip to main content
SpringerLink
Log in

Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review

  • Reviews
  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that suddenly emerged at the end of December 2019 and caused coronavirus disease 2019 (COVID-19) continues to afflict humanity, not only seriously affecting healthcare systems but also leading to global social and economic imbalances. As of August 2022, there were approximately 580 million confirmed cases of COVID-19 and approximately 6.4 million confirmed deaths due to this disease. The data are sufficient to highlight the seriousness of SARS-CoV-2 infection. Although most patients with COVID-19 present primarily with respiratory symptoms, an increasing number of extrapulmonary systemic symptoms and manifestations have been associated with COVID-19. Since the outbreak of COVID-19, much has been learned about the disease and its causative agent. Therefore, great effort has been aimed at developing treatments and drug interventions to treat and reduce the incidence of COVID-19. In this narrative review, we provide a brief overview of the epidemiology, mechanisms, clinical manifestations, diagnosis, and therapeutics of COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020,5(4):536–544

    Article  Google Scholar 

  2. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses, 2020,12(2):135

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020,324(8):782–793

    Article  CAS  PubMed  Google Scholar 

  4. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020,395(10223):470–473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020,395(10223):514–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rimmer A. Covid-19: doctors in final trimester of pregnancy should avoid direct patient contact. BMJ, 2020,368:m1173

    Article  Google Scholar 

  7. Acter T, Uddin N, Das J, et al. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ, 2020,730:138996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rehman SU, Shafique L, Ihsan A, et al. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2. Pathogens, 2020,9(3):240

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol, 2019,17(3):181–192

    Article  CAS  PubMed  Google Scholar 

  10. Mittal A, Manjunath K, Ranjan RK, et al. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog, 2020;16(8):e1008762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mollaei HR, Afshar AA, Kalantar-Neyestanaki D, et al. Comparison of five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR. Iran J Microbiol, 2020,12(3):185–193

    PubMed  PubMed Central  Google Scholar 

  12. Sanders W, Fritch EJ, Madden EA, et al. Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses. bioRxiv, 2020:2020.06.15.153197

  13. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J, 2019,16(1):69

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 2020,92(10):2249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mercurio I, Tragni V, Busto F, et al. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Cell Mol Life Sci, 2021,78(4):1501–1522

    Article  CAS  PubMed  Google Scholar 

  16. Mahmoud IS, Jarrar YB, Alshaer W, et al. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Biochimie, 2020,175:93–98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun, 2020,525(1):135–140

    Article  PubMed  PubMed Central  Google Scholar 

  18. Gussow AB, Auslander N, Faure G, et al. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci USA, 2020,117(26):15193–15199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim D, Lee JY, Yang JS, et al. The Architecture of SARS-CoV-2 Transcrrptome. Cell, 2020,181(4):914–921.e10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wu J, Li J, Zhu G, et al. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Clin J Am Soc Nephrol, 2020,15(8):1139–1145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223):497–506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Harcourt J, Tamin A, Lu X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis, 2020,26(6):1266–1273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020,92(4):441–447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ye Z, Zhang Y, Wang Y, et al. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol, 2020,30(8):4381–4389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Imai K, Tabata S, Ikeda M, et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. J Clin Virol, 2020,128:104393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yang K. What Do We Know About Remdesivir Drug Interactions?. Clin Transl Sci, 2020,13(5):842–844

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano, 2020,14(4):3822–3835

    Article  CAS  PubMed  Google Scholar 

  28. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol, 2020,92(9):1518–1524

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ascierto PA, Fox BA, Urba WJ, et al. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer, 2020,8(1):e000878

    Article  PubMed  PubMed Central  Google Scholar 

  30. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci, 2004,25(6):291–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID-19. Heart, 2020,106(15):1132–1141

    Article  CAS  PubMed  Google Scholar 

  32. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol, 2004,136(1):95–103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pruijssers AJ, George AS, Schafer A, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep, 2020,32(3):107940

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Azevedo RB, Botelho BG, Hollanda JVG, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens, 2021,35(1):4–11

    Article  CAS  PubMed  Google Scholar 

  35. Hussain N, Yoganathan A, Hewage S, et al. The effect of antivirals on COVID-19: a systematic review. Expert Rev Anti Infect Ther, 2021,19(4):473–486

    Article  CAS  PubMed  Google Scholar 

  36. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India, 2020,76(4):370–376

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fang QQ, Huang WJ, Li XY, et al. Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology, 2020,545:1–9

    Article  CAS  PubMed  Google Scholar 

  38. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther, 2020,209:107512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hossen MS, Barek MA, Jahan N, et al. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr Clin Med, 2020,2(10):1777–1789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci, 2020,253:117592

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gupta R, Dhamija P. Sofosbuvir for COVID-19 infection: A potential candidate. Indian J Pharmacol, 2020,52(3):232–233

    Article  PubMed  PubMed Central  Google Scholar 

  42. Uzunova K, Filipova E, Pavlova V, et al. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother, 2020,131:110668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. White NJ, Watson JA, Hoglund RM, et al. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med, 2020,17(9):e1003252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020,30(3):269–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Satarker S, Ahuja T, Banerjee M, et al. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. Curr Pharmacol Rep, 2020,6(5):203–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents, 2020,56(2):105998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Lipworth BJ, Chan R, Kuo CR. Tocilizumab for severe COVID-19 pneumonia. Lancet Rheumatol, 2020,2(11):e660

    Article  PubMed  PubMed Central  Google Scholar 

  48. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv, 2020,4(7):1307–1310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, 2020,178:104787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol, 2020,86:106749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 2020,395(10223):497–506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Shyu D, Dorroh J, Holtmeyer C, et al. Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. Mo Med, 2020,117(3):184–195

    PubMed  PubMed Central  Google Scholar 

  53. Jacofsky D, Jacofsky EM, Jacofsky M. Understanding Antibody Testing for COVID-19. J Arthroplasty, 2020,35(7S):S74–S81

    Article  PubMed  PubMed Central  Google Scholar 

  54. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol, 2020,94(13):e00647–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020,181(2):281–292.e6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Augustine R, Das S, Hasan A, et al. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med, 2020,9(10):3372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Prazuck T, Colin M, Giachè S, et al. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS One, 2020,15(9):e0237694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Weissleder R, Lee H, Ko J, et al. COVID-19 diagnostics in context. Sci Transl Med, 2020,12(546):eabc1931

    Article  CAS  PubMed  Google Scholar 

  59. Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis, 2020,39(6):1011–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med, 2020,14(2):126–135

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ahidjo BA, Loe MWC, Ng YL, et al. Current Perspective of Antiviral Strategies against COVID-19. ACS Infect Dis, 2020,6(7):1624–1634

    Article  CAS  PubMed  Google Scholar 

  62. Bauchner H, Fontanarosa PB. Randomized Clinical Trials and COVID-19: Managing Expectations. JAMA, 2020,323(22):2262–2263

    Article  CAS  PubMed  Google Scholar 

  63. Malik S, Gupta A, Zhong X, et al. Emerging Therapeutic Modalities against COVID-19. Pharmaceuticals (Basel), 2020,13(8):188

    Article  CAS  PubMed  Google Scholar 

  64. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis, 2023,76(3):e342–e349

    Article  CAS  PubMed  Google Scholar 

  65. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 2018,9(2):e00221–18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Chen J, Lin S, Niu C, et al. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med, 2021,15(2):257–265

    Article  CAS  PubMed  Google Scholar 

  67. Plantone D, Koudriavtseva T. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig, 2018,38(8):653–671

    Article  CAS  PubMed  Google Scholar 

  68. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther, 2020,14(1):58–60

    Article  CAS  PubMed  Google Scholar 

  69. Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol, 2020,38(4):379–381

    Article  CAS  PubMed  Google Scholar 

  70. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA, 2020,324(11):1048–1057

    Article  CAS  PubMed  Google Scholar 

  71. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther, 2020,209:107512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X, 2020,2(2):100029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 2020,9(1):382–385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Puoci F. “Monoclonal-Type” Plastic Antibodies for COVID-19 Treatment: What Is the Idea?. J Funct Biomater, 2020,11(2):43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Graham BS. Advances in antiviral vaccine development. Immunol Rev, 2013,255(1):230–242

    Article  PubMed  Google Scholar 

  76. Afrough B, Dowall S, Hewson R. Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol, 2019,196(2):157–166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Fidel PL Jr, Noverr MC. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?. mBio, 2020,11(3):e00907–20

    Article  PubMed  PubMed Central  Google Scholar 

  78. Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: are we protected from COVID-19?. Public Health, 2020,185:91–92

    Article  CAS  PubMed  Google Scholar 

  79. Ankcorn M, Gallacher J, Ijaz S, et al. Convalescent plasma therapy for persistent hepatitis E virus infection. J Hepatol, 2019,71(2):434–438

    Article  PubMed  PubMed Central  Google Scholar 

  80. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med, 2016,374(1):33–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA, 2020,323(16):1582–1589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA, 2020,323(16):1561–1562

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Na-na Xie, Wen-cong Zhang, Jia Chen, Fang-bing Tian & Jian-xin Song

Authors
  1. Na-na Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen-cong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fang-bing Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian-xin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-xin Song.

Ethics declarations

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, Nn., Zhang, Wc., Chen, J. et al. Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review. CURR MED SCI 43, 1066–1074 (2023). https://doi.org/10.1007/s11596-023-2797-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-023-2797-3

Key words

Search

Navigation